Integrin activation controls metastasis in human breast cancer.

By B. Felding‐Habermann, T. O’Toole, Jeffrey W. Smith, E. Fransvea, Zaverio M. Ruggeri, M. Ginsberg, P. Hughes, N. Pampori, S. Shattil, A. Saven and 1 more. Proceedings of the National Academy of Sciences of the United States of America, 2001

612 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Integrin signalling during tumour progression (2004, background): “After reaching the bloodstream, either directly or through the lymphatic system, tumour cells often adhere to PLATELETS and leukocytes, forming emboli that stop in the microcirculation of target organs more easily than isolated tumour cell”
Cancer metastasis: building a framework. (2006, background): “αVβ3 and α3β1 integrins have also been implicated in later stages of metastasis, specifically during adhesion of circulating tumor cells to the vasculature (Felding-Habermann et al., 2001; Wang et al., 2004).”
Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation (2010, background): “It has been shown that activation of v 3 is required for metastasis in a breast cancer carcinoma model [93] and that expression of v 3 and v 5 in tumor vasculature correlates with the malignancy of neuroblastoma [94, 95].”
Integrins in cancer: biological implications and therapeutic opportunities (2010, positive): “This interaction facilitates tumour cell arrest in the vasculature, leading to metastasis to various sites, including the bone marro”
Contribution of platelets to tumour metastasis (2011, background): “Analysing the adhesive behaviour of blood-borne tumour cells in a blood perfusion model revealed that tumour cells can also express key integrins, such as αvβ3, in distinct states of activatio”